Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography

List of Tables

The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.

Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.

Market Trends of the Glaucoma Therapeutics Market:

The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.

Glaucoma therapeutics Market: Segmental Overview

The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.

By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.

The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.

By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.

Glaucoma therapeutics Market: Geographical Overview

The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.

Product Code: TIPRE00018828

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Glaucoma Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Glaucoma Therapeutics Market - Key Market Dynamics

5.1 Glaucoma Therapeutics Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Mounting Incidence of Glaucoma Disease
- 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
5.3 Market Restraints
- 5.3.1 Medication Regimen Compliance Issues
5.4 Market Opportunities
- 5.4.1 Development of Wearable Technologies
5.5 Future Trends
- 5.5.1 Development of Novel Drug Delivery Methods
5.6 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - Global Market Analysis

6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
6.2 Glaucoma Therapeutics Market Forecast Analysis

7. Glaucoma Therapeutics Market Analysis - by Drug Class

7.1 Beta Blockers
- 7.1.1 Overview
- 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Alpha Adrenergic Agonists
- 7.2.1 Overview
- 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Prostaglandins Analogues
- 7.3.1 Overview
- 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Carbonic Anhydrase Inhibitors
- 7.4.1 Overview
- 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Combination Drugs
- 7.5.1 Overview
- 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Glaucoma Therapeutics Market Analysis - by Indication

8.1 Open Angle Glaucoma
- 8.1.1 Overview
- 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Angle Closure Glaucoma
- 8.2.1 Overview
- 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Glaucoma Therapeutics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. Glaucoma Therapeutics Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Glaucoma Therapeutics Market Overview
- 10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3 Europe
- 10.3.1 Europe Glaucoma Therapeutics Market Overview
- 10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4 Asia Pacific
- 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
- 10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
- 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6 South and Central America
- 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
- 10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
  - 10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
  - 10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
    - 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

11.1 Growth Strategies in Glaucoma Therapeutics Market
11.2 Organic Growth Strategies
- 11.2.1 Overview
11.3 Inorganic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Alcon AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 AbbVie Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Bausch & Lomb Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Fera Pharmaceuticals, LLC
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Viatris Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Novartis AG
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Sun Pharmaceutical Industries Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Teva Pharmaceutical Industries Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Thea Pharma Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Santen Pharmaceutical Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms